MarketBeat Daily Ratings for Thursday, July 3, 2025
Ratings changes for Meta Platforms, HIVE Digital Technologies, NV5 Global, Primoris Services, Absci, Veritone, Disc Medicine and more...Text "MarketBeat" to 68285 to get SMS breaking news alerts for stocks on your watchlist and other special reports. Learn More.July 3rd, 2025 Today's Top Stories | | By Ryan Hasson | July 3, 2025 06:07 AM |
| | | By The Associated Press | July 3, 2025 12:15 AM |
| | By Leo Miller | July 2, 2025 03:34 PM |
| | | By Jeffrey Neal Johnson | July 2, 2025 03:27 PM |
| | By Leo Miller | July 2, 2025 01:09 PM |
|
|
Analysts' Upgrades | | FedEx (NYSE:FDX) was upgraded by analysts at BNP Paribas Exane from an "underperform" rating to an "outperform" rating. They now have a $270.00 price target on the stock. This represents a 10.6% upside from the current price of $244.18. | | Huntington Bancshares (NASDAQ:HBAN) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $21.00 price target on the stock. This represents a 18.6% upside from the current price of $17.71. | | Meta Platforms (NASDAQ:META) was upgraded by analysts at Needham & Company LLC from an "underperform" rating to a "hold" rating.The current price is $721.60. | | United Parcel Service (NYSE:UPS) was upgraded by analysts at BNP Paribas Exane from an "underperform" rating to a "neutral" rating. They now have a $100.00 price target on the stock. This represents a 5.5% downside from the current price of $105.84. | | Valley National Bancorp (NASDAQ:VLY) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $11.00 price target on the stock. This represents a 13.7% upside from the current price of $9.68. |
|
View More Upgrades
|
Analysts' New Coverage | | Absci (NASDAQ:ABSI) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $7.00 price target on the stock. This represents a 155.9% upside from the current price of $2.74. | | argenex (NASDAQ:ARGX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $700.00 price target on the stock. This represents a 29.2% upside from the current price of $541.85. | | Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $250.00 price target on the stock. This represents a 44.1% upside from the current price of $173.55. | | Axsome Therapeutics (NASDAQ:AXSM) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $190.00 price target on the stock. This represents a 82.6% upside from the current price of $104.05. | | BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $97.00 price target on the stock. This represents a 67.4% upside from the current price of $57.94. | | Certara (NASDAQ:CERT) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $16.00 price target on the stock. This represents a 40.1% upside from the current price of $11.42. | | Disc Medicine (NASDAQ:IRON) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $85.00 price target on the stock. This represents a 58.9% upside from the current price of $53.49. | | Kymera Therapeutics (NASDAQ:KYMR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $70.00 price target on the stock. This represents a 56.5% upside from the current price of $44.74. | | Primoris Services (NASDAQ:PRIM) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating and a $102.00 price target on the stock. This represents a 23.0% upside from the current price of $82.91. | | Recursion Pharmaceuticals (NASDAQ:RXRX) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $5.00 price target on the stock. This represents a 4.1% downside from the current price of $5.22. | | Sana Biotechnology (NASDAQ:SANA) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $12.00 price target on the stock. This represents a 292.7% upside from the current price of $3.06. | | Schrodinger (NASDAQ:SDGR) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $28.00 price target on the stock. This represents a 32.7% upside from the current price of $21.11. | | Telix Pharmaceuticals (NASDAQ:TLX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $23.00 price target on the stock. This represents a 42.4% upside from the current price of $16.16. |
|
View More New Coverage
|
Calendars from MarketBeat | |
|
| Get 30 Days of MarketBeat All Access Free | | Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: | Best-in-Class Portfolio MonitoringView the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Stock Ideas and RecommendationsGet daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.Advanced Stock Screeners and Research ToolsIdentify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. | | Start Your 30-Day Free Trial |
| Upgrade Your Subscription | | Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET. | | Upgrade Now |
|
| Manage Your Watchlist | | View and add up to ten holdings to your watchlist. | | View My Portfolio |
|
| Join Our Facebook Group | | Join MarketBeat’s free stock discussion and trading idea group on Facebook. | | Join Now |
|
Thank you for subscribing to MarketBeat!We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
© 2006-2025 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States. Today's Bonus Content: The options market leaves “clues” on Wall Street's next move (Click to Opt-In) |
